Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A basket study of ALPN-303 renal, hematologic, and/or dermatologic indications

Next Previous
Search
Trial Profile

A basket study of ALPN-303 renal, hematologic, and/or dermatologic indications

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Povetacicept (Primary)
  • Indications Haematological disorders; Renal impairment; Skin disorders
  • Focus Therapeutic Use

Most Recent Events

  • 14 Nov 2022 According to an Alpine Immune Sciences media release, initial clinical data from the basket studies expected in late 2023.
  • 14 Nov 2022 According to an Alpine Immune Sciences media release, data from this study were presented at the R&D Day on Sep 2022.
  • 11 Aug 2022 According to an Alpine Immune Sciences media release, this trial is expected to begin in the first half of 2023 and initial clinical data from the basket trials expected in the second half of 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top